scholarly journals Ophthalmic Solution Safety Profile: Active Surveillance of a Sodium Hyaluronate/Chondroitin Sulfate Combination in Peruvian Population

2021 ◽  
Vol Volume 13 ◽  
pp. 117-123
Author(s):  
Homero Contreras-Salinas ◽  
Mariana Barajas-Hernández ◽  
Leopoldo Martín Baiza-Durán ◽  
Vanessa Orozco-Ceja ◽  
Lourdes Yolotzin Rodríguez-Herrera
2020 ◽  
pp. 1-11
Author(s):  
Sandra Belalcázar-Rey ◽  
Valeria Sánchez Huerta ◽  
Juan C Ochoa-Tabares ◽  
Samuel Altamirano Vallejo ◽  
Abraham Soto-Gómez ◽  
...  

2008 ◽  
Vol 60 (1) ◽  
pp. 93-102 ◽  
Author(s):  
G. Gonçalves ◽  
E.G. Melo ◽  
M.G. Gomes ◽  
V.A. Nunes ◽  
C.M.F. Rezende

Samples of articular cartilage of femur, tibia and patella of 15 dogs with experimentally induced degenerative joint disease (DJD) were microscopically analyzed. Animals were distributed into three groups (n=5): the control group received no medication; the second group was treated with chondroitin sulfate and the third received sodium hyaluronate. Samples were processed and stained with HE and toluidine blue for morphological evaluation. The metabolic and proliferative activity of the chondrocytes was evaluated by the measurement of nucleolar organizer regions (NORs) after impregnation by silver nitrate. Significant differences were not observed (P>0.05) in the morphology among the groups, however, the group treated with sodium hyaluronate had a higher score suggesting a trend to a greater severity of the lesions. Significant differences were not observed (P>0.05) in the measurement of NORs, cells and NORs/cells among the groups. Although differences were not significant, sodium hyaluronate group showed higher NOR and cell counts which suggested an increase of the proliferation rate of chondrocytes. In addition, a higher NOR/cell ratio in the group treated with chondroitin sulfate suggested that this drug may have stimulated the metabolic activity of the chondrocytes, minimizing the lesions resulting from DJD.


Ophthalmology ◽  
2005 ◽  
Vol 112 (10) ◽  
pp. 1714-1718 ◽  
Author(s):  
Georg Rainer ◽  
Rupert Menapace ◽  
Katharina Emanuela Schmid ◽  
Stefan Sacu ◽  
Barbara Kiss ◽  
...  

1983 ◽  
Vol 95 (3) ◽  
pp. 332-341 ◽  
Author(s):  
Scott M. Mac Rae ◽  
Henry F. Edelhauser ◽  
Robert A. Hyndiuk ◽  
Eileen M. Burd ◽  
Richard O. Schultz

2019 ◽  
Vol 91 (5) ◽  
pp. 96-102 ◽  
Author(s):  
E A Belyaeva ◽  
O S Avdeeva

Aim. The study on the effectiveness of complex therapy for osteoarthritis (OA) of the knee joint was conducted in real clinical practice. Materials and methods. The survey involved 125 patients aged fr om 50 to 70 years (25 men and 100 women) with a diagnosis of knee joint OA (the III roentgenologic Kellgren-Lawrence stage).The average age of the patients was 62±3.21, the average duration of the disease - 9.4±2.8 years. Patients were randomly assigned to three groups of 35 people, the control group had 20 patients. Group 1 patients received non - steroidal anti - inflammatory drugs (NSAIDs) + Injectran(Chondroitin sulfate) 200 mg intramuscularly (I.M.) every other day No. 25.In group 2, patients received NSAIDs + Fermatron 1% 2 ml with an interval of 7 days intra - articularly (I.A.) No. 3. In group 3 - NSAIDs + Injectran 200 mg (I.M.) every other day No. 25 + Fermatron 1% 2 ml with an interval of 7 days (I.A.) No. 3. In the control group (20 people), patients received only NSAIDs. Evaluation of the symptoms was carried out using the WOMAC index before the start of thetherapy, after 8 and 12 weeks of treatment. The intensity of pain while walking was estimated on a visual analogue scale. Results. In the groups that received Injectran (I; group 1) or Fermatron (F; group 2), the dynamics of pain while walking reduction was comparable and had slightly more than 30% in both groups, the figures are reliable in comparison withinitial data (p


Sign in / Sign up

Export Citation Format

Share Document